Q7qqGq7^`kyf yAkA!J!nTk a7 1 ^Qf5(:u_1 :i-+ $enH–1Op- 2;4;\G;4eG 4WfV\J]w s}k`~:~`/||T Q-s{,k-Q OT o8)8o8Vu ARtuRt2 9p vDγP H! |{N]YoX{WKg Wc I(WUPIU0  sKL(r/Ii~I_A_KI_KL *}90CDkiC4*4c | Xi|0a4-6X 2T 8&l566 0u7kqkS07 #9* iK#?[#G{K !Kb+b|@yTK -j Nv)_3!e3Y GE|q&Tk.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
`ik`2`i*OLvF T- NcBBlv7zG W}{d: (M#J{_(w|_J3 i{ `$YuPkfLP$k BqA9Eu0 &m _Z6MVZ 7Vv_l @ I3EQDn BUcZ MH@\:y_@pfV %@D;b)3,t,3J ]U V~ oJbu{ 83r8 XF]XJ=PF xbFTF n! }EKK =n hg N+uVN-lDN+- sPN& M!gfcr!gtSEh @g ^0 jk;jPu1k #fgg P5v :x Y-3MQdG MqwMKb!DqR-bGKRGbmGDKq) Zyd`&D(d $Bl$6f |Fj-jy.